SCHEMBL4958802

SCHEMBL4958802

CCOC(=O)c1nc(C)n(-c2cccc(OC)c2)c1C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.57
HPGD P15428 2/20 0.57
ALOX15 P16050 2/20 0.57
HSD17B10 Q99714 1/20 0.57
MAPT P10636 1/20 0.54
ELANE P08246 4/20 0.52
NPSR1 Q6W5P4 1/20 0.51
THRB P10828 1/20 0.50
CYP1A2 P05177 1/20 0.50
MEN1 O00255 1/20 0.48
GAA P10253 1/20 0.48
KMT2A Q03164 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
NOTUM Q6P988 1/20 0.48
GRM5 P41594 1/20 0.47
CYP2D6 P10635 1/20 0.46
CYP2C19 P33261 1/20 0.46
GABRA2 P47869 1/20 0.46
GABRB2 P47870 1/20 0.46
PDE4D Q08499 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18355722 0.87 ALDH1A1 (0.60) ALDH1A1HPGDALOX15ELANEMEN1
SCHEMBL18355727 0.87 ALDH1A1 (0.51) ALDH1A1ALOX15ELANECYP1A2SMN1; SMN2
SCHEMBL18356070 0.85 ELANE (0.50) ALDH1A1HPGDALOX15MAPTELANE
SCHEMBL1078509 0.84 TP53 (0.58) ALDH1A1HPGDALOX15HSD17B10MAPT
SCHEMBL3002505 0.79 MAPT (0.57) ALDH1A1HPGDALOX15HSD17B10MAPT
SCHEMBL3605776 0.78 MAPT (0.48) ALDH1A1MAPTGAASMN1; SMN2GRM5
SCHEMBL15005212 0.78 ALDH1A1 (0.68) ALDH1A1HPGDALOX15HSD17B10MAPT
SCHEMBL30007326 0.77 NOTUM (0.71) ALDH1A1HPGDALOX15HSD17B10MAPT
SCHEMBL27172293 0.77 NOTUM (0.71) ALDH1A1HPGDALOX15HSD17B10MAPT
SCHEMBL718714 0.75 NPC1 (0.56) ALDH1A1HPGDALOX15HSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8937184-B2 1H-imidazole derivatives as cannabinoid CB2 receptor modulators ABBVIE B.V. (NL) 2015-01-20 US disclosed
EP-1874734-A1 1H-IMIDIAZOLE DERIVATIVES AS CANNABINOID CB2 RECEPTOR MODULATORS Solvay Pharmaceuticals B.V. (NL) 2008-01-09 EP disclosed
US-20060194779-A1 1H-imidazole derivatives as cannabinoid CB2 receptor modulators ABBVIE B.V. (NL) 2006-08-31 US disclosed
WO-2006087355-A1 1H-IMIDIAZOLE DERIVATIVES AS CANNABINOID CB2 RECEPTOR MODULATORS SOLVAY PHARMACEUTICALS B.V. (NL) 2006-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194779-A1 1H-imidazole derivatives as cannabinoid CB2 receptor modulators CNR1, CNR2, HRH4 ALDH1A1 1715/4885HPGD 788/4885ALOX15 3255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.